Impact of the counterion on the solubility and physicochemical properties of salts of carboxylic acid drugs

Drug Development and Industrial Pharmacy

Volumn 38, Issue 1, 2012, Pages 93-103

  David, S E ^a,c   Timmins, P ^b   Conway, B R ^c,d  

^a GLAXOSMITHKLINE   (United Kingdom)

^b BRISTOL MYERS SQUIBB   (United States)

^c ASTON UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF HUDDERSFIELD   (United Kingdom)

Author keywords

Counterion; Etodolac; Flurbiprofen; Gemfibrozil; Ibuprofen; Salt selection; Solubility; Tris(hydroxymethyl)aminomethane

Indexed keywords

2 AMINO 2 METHYLPROPAN 1 OL; 2 AMINO 2 METHYLPROPAN 1,3 DIOL; BENZYLAMINE; BUTYLAMINE; COUNTERION; CYCLOHEXYLAMINE; ETODOLAC; FLURBIPROFEN; GEMFIBROZIL; HEXYLAMINE; IBUPROFEN; KETOROLAC TROMETAMOL; OCTYLAMINE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

AQUEOUS SOLUTION; ARTICLE; CRYSTAL STRUCTURE; DENSITY; DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; DRUG SOLUBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFRARED SPECTROSCOPY; PROTON NUCLEAR MAGNETIC RESONANCE; THERMOGRAVIMETRY; WATER VAPOR; X RAY DIFFRACTION;

AMINES; CARBOXYLIC ACIDS; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; HYDROGEN BONDING; HYDROGEN-ION CONCENTRATION; IONS; PHARMACEUTICAL PREPARATIONS; SALTS; SOLUBILITY; TRANSITION TEMPERATURE;

EID: 82455188322     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2011.592530     Document Type: Article

References (47)

1. Gould P. (1986). Salt selection for basic drugs. Int J Pharm, 33:201-217.
2. Serajuddin AT. (2007). Salt formation to improve drug solubility. Adv Drug Deliv Rev, 59:603-616.
3. Stahl PH, Wermuth G. (2002). Handbook of pharmaceutical salts: properties, selection, and use. Wiley-VCH, Zurich.
4. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev, 46:3-26.
5. Bastin RJ, Bowker MJ, Slater BJ. (2000). Salt selection and optimization procedures for pharmaceutical new chemical entities. Org Proc Res Dev, 4:427-435.
6. Black SN, Collier EA, Davey RJ, Roberts RJ. (2007). Structure, solubility, screening, and synthesis of molecular salts. J Pharm Sci, 96:1053-1068.
7. Morris KR, Fakes MG, Thakur AB, Newman AW, Singh AK, Venit JJ., Spagnuluo CG, Serajuddin ATM. (1994). An integrated approach to the selection of optimal salt form for a new drug candidate. Int J Pharm, 105:209-217.
8. Lee T, Wang YW. (2009). Initial salt screening procedures for manufacturing ibuprofen. Drug Dev Ind Pharm, 35:555-567.
9. Datta S, Grant DJ. (2004). Crystal structures of drugs: advances in determination, prediction and engineering. Nat Rev Drug Discov, 3:42-57.
10. York P. (1992). Crystal engineering and particle design for the powder compaction process. Drug Dev Ind Pharm, 18:677-721.
11. Paulekuhn GS, Dressman JB, Saal C. (2007). Trends in active pharmaceutical ingredient salt selection based on analysis of the Orange Book database. J Med Chem, 50:6665-6672.
12. Guerrieri P, Rumondor AC, Li T, Taylor LS. (2010). Analysis of relationships between solid-state properties, counterion, and developability of pharmaceutical salts. AAPS Pharmscitech, 11:1212-1222.
13. Chowan ZT. (1978). pH-solubility profiles of organic carboxylic acids and their salts. J Pharm Sci, 67:1257-1260.
14. Anderson BD, Conradi RA. (1985). Predictive relationships in the water solubility of salts of a nonsteroidal anti-inflammatory drug. J Pharm Sci, 74:815-820.
15. Forbes RT, York P, Davidson JR. (1995). Dissolution kinetics and solubilities of p-aminosalicylic acid and its salts. Int J Pharm, 126:199-208.
16. Cheong HA, Choi HK. (2002). Enhanced percutaneous absoption of piroxicam via salt formation with ethanolamines. Pharm Res, 19:1375-1380.
17. O'Connor KM, Corrigan OI. (2001). Comparison of the physicochemical properties of the N-(2-hydroxyethyl) pyrrolidine, diethylamine and sodium salt forms of diclofenac. Int J Pharm, 222:281-293.
18. O'Connor KM, Corrigan OI. (2001). Preparation and characterization of a range of diclofenac salts. Int J Pharm, 226:163-179.
19. Fini A, Fazio G, Fetoci G. (1995). Solubility and solubilization properties of non-steroidal anti-inflammatory drugs. Int J Pharm, 126:95-102.
20. Fini A, Fazio G, Benetti L, Ghedini V. (2007). Thermal analysis of some diclofenac salts with alkyl and alkylhydroxy amines. Thermochim Acta, 464:65-74.
21. Gu L, Strickley RG. (1987). Preformulation salt selection. Physical property comparisons of the tris(hydroxymethyl)aminomethane (THAM) salts of four analgesic/antiinflammatory agents with the sodium salts and the free acids. Pharm Res, 4:255-257.
22. Shaw LR, Irwin WJ, Grattan TJ, Conway BR. (2005). The effect of selected water-soluble excipients on the dissolution of paracetamol and ibuprofen. Drug Dev Ind Pharm, 31:515-525.
23. Silverstein RM, Webster FX. (1998). Spectrometric identification of organic compounds. John Wiley & Sons, New York, USA.
24. Palomo ME, Ballesteros MP, Frutos P. (1999). Analysis of diclofenac sodium and derivatives. J Pharm Biomed Anal, 21:83-94.
25. Socrates G. (1994). Infrared characteristic group frequencies. John Wiley & Sons, New York, USA.
26. Yalkowsky SH. (1981). Solubility and partitioning V: dependence of solubility on melting point. J Pharm Sci, 70:971-973.
27. Yalkowsky SH, Flynn GL, Slunick TG. (1972). Importance of chain length on physicochemical and crystalline properties of organic homologs. J Pharm Sci, 61:852-857.
28. Forster S, Buckton G, Beezer AE. (1991). The importance of chain length on the wettability and solubility of organic homologs. Int J Pharm, 72:29-34.
29. Dean PM, Golding JJ, Pringle JM, Forsyth M, Skelton BW, White AH, MacFarlane DR. (2009). The effect of alkyl chain length in a series of novel N-alkyl-3-benzylimidazolium iodide salts. Cryst Eng Comm, 11:2456-2465.
30. Thomas E, Rubino J. (1996). Solubility, melting point and saltingout relationships in a group of secondary amine hydrochloride salts. Int J Pharm, 130:179-185.
31. Wells JI, Aulton, ME.(2007). Pharmaceutical Preformulation. In Aulton ME ed. Pharmaceutics: The design and manufacture of medicines. London: Elsevier, 336-360.
32. Callahan JC, Cleary GW, Elefant M, Kaplan G, Kensler T, Nash RA. (1982). Equilibrium moisture content of pharmaceutical excipients. Drug Dev Ind Pharm, 8:355-69.
33. Balbach S, Korn C. (2004). Pharmaceutical evaluation of early development candidates "the 100 mg-approach". Int J Pharm, 275:1-12.
34. Sun CC. (2005). True density of microcrystalline cellulose. J Pharm Sci, 94:2132-2134.
35. Heckel RW. (1961). Density-pressure relations in powder compaction. Trans Metallogr Soc AIME, 221:671-675.
36. Sun CC. (2005). Quantifying errors in tableting data analysis using the Ryshkewitch equation due to inaccurate true density. J Pharm Sci, 94:2061-2068.
37. Ledwidge MT. (1997). The effects of pH, crystalline phase and salt formation on the solubility of ionisable drugs. University of Dublin, Dublin, Ireland. PhD thesis. 0
38. Agharkar S, Lindenbaum S, Higuchi T. (1976). Enhancement of solubility of drug salts by hydrophilic counterions: properties of organic salts of an antimalarial drug. J Pharm Sci, 65:747-749.
39. Parshad H, Frydenvang K, Liljefors T, Sorensen HO, Larsen C. (2004). Aqueous solubility study of salts of benzylamine derivatives and p-substituted benzoic acid derivatives using X-ray crystallographic analysis. Int J Pharm, 269:157-168.
40. Fini A, Fazio G, Fernandez-Hervas MJ, Holgado MA, Rabasco AM. (1996). Factors governing the dissolution of diclofenac salts. Eur J Pharm Sci, 4:231-238.
41. Cheung EY, David SE, Harris KDM, Conway BR, Timmins P. (2007). Structural properties of a family of hydrogen-bonded co-crystals formed between gemfibrozil and hydroxy derivatives of t-butylamine, determined directly from powder X-ray diffraction data, J Solid State Chem, 180:1068-1075.
42. David SE, Ramirez M, Timmins P, Conway BR. (2010). Comparative physical, mechanical and crystallographic properties of a series of gemfibrozil salts. J Pharm Pharmacol, 62:1519-1525.
43. Luner PE, Babu SR, Radebaugh GW. (1994). The effect of bile salts and lipids on the physicochemical behaviour of gemfibrozil. Pharm Res, 11:1755-1760.
44. David SE, Timmins P, Irwin WJ, Conway BR. (2005). The effect of added counterions on the mechanical properties of a poorly compressible drug, gemfibrozil. Proc Pharm Sci Fair, Nice, 2005.
45. Lee YJ, Padula J, Lee HK. (1988). Kinetics and mechanisms of etodolac degradation in aqueous solutions. J Pharm Sci, 77:81-86.
46. Gerbino PP. (2006). Remington: The Science and Practice of Pharmacy, 21st Ed., Philadelphia, PA. Lippincott, Williams & Wilkins.
47. Slater B, McCormack A, Avdeef A, Comer JE. (1994). pH-metric log P. 4. Comparison of partition coefficients determined by HPLC and potentiometric methods to literature values. J Pharm Sci, 83:1280-1283.